{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:16:31Z","timestamp":1775477791689,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jhepr.2026.101754","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:42:51Z","timestamp":1769733771000},"page":"101754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal trends and racial\/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-3954","authenticated-orcid":false,"given":"Wenzhan","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-4586","authenticated-orcid":false,"given":"Hang","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101754_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101754_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101754_bib3","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101754_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101754_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101754_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000190","article-title":"Addressing racial and ethnic disparities in US liver cancer care","volume":"7","author":"Kim","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101754_bib7","first-page":"408","article-title":"Prevalence of viremic hepatitis C virus infection by age, race\/ethnicity, and birthplace and disease awareness among viremic persons in the United States, 1999\u20132016","volume":"221","author":"Zou","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101754_bib8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","author":"Lim","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101754_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/ciad411","article-title":"Estimated prevalence and awareness of hepatitis C virus infection among US adults: national health and nutrition examination survey, january 2017\u2013march 2020","volume":"77","author":"Lewis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101754_bib10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101754_bib11","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/cncr.30103","article-title":"Race\/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States","volume":"122","author":"Ha","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.101754_bib12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1053\/j.gastro.2019.12.030","article-title":"Recent decline in hepatocellular carcinoma rates in the United States","volume":"158","author":"Shiels","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101754_bib13","article-title":"Trends in hepatocellular carcinoma stage by racial\/ethnic group in the United States, 1992-2019","volume":"5","author":"Alvarez","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101754_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.32394","article-title":"Racial\/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992\u20132018","volume":"76","author":"Alvarez","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101754_bib15","first-page":"172","article-title":"Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: a nationwide analysis of two decades","volume":"12","author":"Abboud","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jhepr.2026.101754_bib16","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program (NCI SEER). Number of persons by race and hispanic ethnicity for SEER participants (2020 Census data). Accessed April 30, 2025. https:\/\/seer.cancer.gov\/registries\/data.html#a5."},{"key":"10.1016\/j.jhepr.2026.101754_bib17","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\u2217Stat database: incidence - SEER research Plus limited-field data, 21 Registries, Nov 2024 Sub (2000-2022), national cancer Institute, DCCPS, surveillance research Program, released April 2025, based on the November 2024 submission."},{"key":"10.1016\/j.jhepr.2026.101754_bib18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","article-title":"Future of hepatocellular carcinoma incidence in the United States forecast through 2030","volume":"34","author":"Petrick","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101754_bib19","unstructured":"National Cancer Institute, Surveillance, epidemiology, and End results Program (NCI SEER). U.S. County population data - 1969-2023. Published online February 2025. Accessed March 13, 2025. https:\/\/seer.cancer.gov\/popdata\/."},{"key":"10.1016\/j.jhepr.2026.101754_bib20","series-title":"Surveillance, Epidemiology, and End results Program (NCI SEER). SEER data change history","year":"2025"},{"key":"10.1016\/j.jhepr.2026.101754_bib21","series-title":"Suppression of rates and counts","year":"2024"},{"key":"10.1016\/j.jhepr.2026.101754_bib22","unstructured":"National Cancer Institute, Surveillance, epidemiology, and End results Program (NCI SEER). Impact of COVID-19 on SEER data releases. Accessed April 22, 2025. https:\/\/seer.cancer.gov\/data\/covid-impact.html."},{"key":"10.1016\/j.jhepr.2026.101754_bib23","unstructured":"Surveillance Research Program, National Cancer Institute SEER\u2217Stat software (seer.cancer.gov\/seerstat) version 8.4.5."},{"key":"10.1016\/j.jhepr.2026.101754_bib24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cgh.2023.08.016","article-title":"Incidence of Etiology-specific Hepatocellular Carcinoma: diverging trends and significant heterogeneity by race and ethnicity","volume":"22","author":"Pinheiro","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101754_bib25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MCG.0000000000001172","article-title":"Among Medicare patients with hepatocellular carcinoma, non-alcoholic fatty liver disease is the most common etiology and cause of mortality","volume":"54","author":"Hester","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101754_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.2020.10121","article-title":"Hepatitis C\u2013related hepatocellular carcinoma incidence in the Veterans health administration after introduction of direct-acting antivirals","volume":"324","author":"Beste","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jhepr.2026.101754_bib27","series-title":"Final recommendation statement hepatitis C: screening","year":"2013"},{"key":"10.1016\/j.jhepr.2026.101754_bib28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.15585\/mmwr.mm7132e1","article-title":"Vital signs: hepatitis C treatment among insured adults \u2014 United States, 2019\u20132020","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jhepr.2026.101754_bib29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/cid\/ciac139","article-title":"Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014\u20132020","volume":"75","author":"Teshale","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101754_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhepr.2026.101754_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2208","article-title":"Liver cancer etiology in asian subgroups and American Indian, Black, Latino, and white populations","volume":"8","author":"Pinheiro","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2026.101754_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21019","article-title":"Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Rodriguez","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2026.101754_bib33","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101754_bib34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2025.03.001","article-title":"Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden","volume":"83","author":"Issa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101754_bib36","series-title":"20.6 million people in the U.S. Identify as asian, native Hawaiian or pacific islander","year":"2022"},{"key":"10.1016\/j.jhepr.2026.101754_bib37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2023.06.026","article-title":"Trends in Medicare spending on oral medications for hepatitis B from 2013 to 2020","volume":"165","author":"Ying","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101754_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir\u2014a propensity score\u2013matched study","volume":"219","author":"Nguyen","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2026.101754_bib39","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592600025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592600025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:36:24Z","timestamp":1775475384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592600025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S258955592600025X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101754","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal trends and racial\/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101754"}}